Loading data for IMMX — first visit, this takes a few seconds.

Preisalarm

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · Echtzeitkurs · USD

11.34

+0.37 (3.37%)

Zum Schluss: Aug 17, 2026, 8:00 PM

11.34

+0.01%

Nachbörslich: 7:34 PM

3.37% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	807.29 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-39.92 Mio
Beta	0.11
EPS (ttm)	-0.91
KGV (TTM)	n/a
Forward-KGV	-12.55
KBV (TTM)	3.54
KUV (TTM)	n/a
Earnings Date	n/a

Brief	n/a
Volumen	1,237,511
Ø Vol. (20D)	1,896,532
Eröffnung	10.88
Vortagesschluss	10.97
Tagesspanne	10.74 - 11.53
52-Wk Range	1.94 - 12.14
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Dec 16, 2021

Mitarbeiter 21

Börse NasdaqCM

Tickersymbol IMMX

Website https://www.immixbio.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Immix Biopharma 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -29.44 Mio, ein Anstieg von 36.21 %.

Finanzberichte

Gewinnüberraschung

Immix Biopharma hat die Quartalszahlen am Aug 7, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.18 verfehlt die Erwartungen um 0.00, mit 18.18% Wachstum im Jahresvergleich.

Nachrichten

vor 4 Wochen · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

vor 2 Monaten · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

vor 2 Monaten · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

vor 2 Monaten · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

vor 3 Monaten · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

Seite 1 von 2

Immix Biopharma Inc. (IMMX)